Theravance Biopharma (TBPH) withholds 7,952 insider shares to cover taxes

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that officer Brett A. Grimaud, SVP, General Counsel and Secretary, had 7,952 Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The shares were withheld by the issuer at a reference value of $16.95 per share and the transaction did not involve an open market trade. Following this tax-withholding disposition, Grimaud directly holds 355,168 Ordinary Shares of Theravance Biopharma, Inc.

Insider Trade Summary

Net Seller: 7,952 shares

Net Sell 1 txn

Insider Grimaud Brett A.

Role SVP, GEN COUNSEL AND SECRETARY

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares F1	7,952	$16.95	$135K

Holdings After Transaction: Ordinary Shares — 355,168 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld for tax obligations: 7,952 shares Reference share value: $16.95 per share Shares owned after transaction: 355,168 shares +1 more

4 metrics

Shares withheld for tax obligations 7,952 shares Ordinary Shares withheld on 2026-08-20 to satisfy tax obligations on RSU vesting

Reference share value $16.95 per share Value used for the 7,952 Ordinary Shares withheld for tax obligations

Shares owned after transaction 355,168 shares Direct Ordinary Share holdings of Brett A. Grimaud following the tax-withholding disposition

Tax-withholding transaction count 1 transaction Number of code F transactions reported in this Form 4

Key Terms

restricted stock units, withheld to satisfy tax obligations, open market transaction

3 terms

restricted stock units financial

"tax obligations arising out of the vesting of previously granted restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

withheld to satisfy tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

open market transaction financial

"did not involve an open market transaction."

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

FAQ

What insider transaction did Theravance Biopharma (TBPH) report for Brett A. Grimaud?

Theravance Biopharma reported that 7,952 Ordinary Shares were withheld from officer Brett A. Grimaud on 2026-08-20 to satisfy tax obligations from vesting restricted stock units. The transaction was with the issuer and did not involve an open market trade.

Was the recent TBPH insider transaction a market sale or a tax withholding?

The reported TBPH insider transaction was a tax-withholding disposition. 7,952 shares were withheld by Theravance Biopharma to satisfy tax obligations upon vesting of restricted stock units and no open market transaction occurred.

What price per share was used in the TBPH insider tax-withholding transaction?

The Form 4 shows a reference value of $16.95 per share for the 7,952 Ordinary Shares withheld from Brett A. Grimaud to cover tax obligations related to vesting restricted stock units.

How many Theravance Biopharma (TBPH) shares does Brett A. Grimaud hold after the transaction?

After the tax-withholding transaction, Brett A. Grimaud directly holds 355,168 Ordinary Shares of Theravance Biopharma, Inc., as reported in the Form 4.

Was the TBPH insider transaction made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the footnote states the shares were withheld by the issuer to satisfy tax obligations, rather than sold under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 06:03 PM Accepted by SEC EDGAR 08/24/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grimaud Brett A.

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GEN COUNSEL AND SECRETARY

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2026		F		7,952(1)	D	$16.95	355,168	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)